Denosumab for bone metastases from breast cancer: A new therapy option?

Journal of Clinical Oncology

Volumn 29, Issue 14, 2011, Pages

  Aapro, Matti S ^a  

^a CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; IMMUNOGLOBULIN G; ZOLEDRONIC ACID;

BONE METASTASIS; BREAST CANCER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; NEPHROTOXICITY; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR;

ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; JAW DISEASES; KIDNEY; OSTEONECROSIS; RANK LIGAND;

EID: 79955838317     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.9150     Document Type: Letter

References (17)

1. Stopeck AT, Lipton A, Body JJ, et al: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 28:5132-5139, 2010
2. Xgeva (denosumab) injection, for subcutaneous use [prescribing information]. Thousand Oaks, CA, Amgen Inc, 2010
3. Fornier MN: Denosumab: Second chapter in controlling bone metastases or a new book? J Clin Oncol 28:5127-5131, 2010
4. Lipton A, Siena S, Rader M, et al: Comparison of denosumab versus zoledronic acid for treatment of bone metastases in advanced cancer patients: An integrated analysis of 3 pivotal trials. Presented at the 35th ESMO Congress, Milan, Italy, October 8-12, 2010 (abstr 1249P).
5. Aapro M, Abrahamsson PA, Body JJ, et al: Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel. Ann Oncol 19:420-432, 2008
6. Perazella MA, Markowitz GS: Bisphosphonate nephrotoxicity. Kidney Int 74:1385-1393, 2008
7. Weitzman R, Sauter N, Eriksen EF, et al: Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients - May 2006. Crit Rev Oncol Hematol 62:148-152, 2007
8. Ripamonti CI, Maniezzo M, Campa T, et al: Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates: The experience of the National Cancer Institute of Milan. Ann Oncol 20:137-145, 2009
9. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
10. Gnant M, Mlineritsch B, Stoeger H, et al: Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrineresponsive early breast cancer. J Clin Oncol 28:75s, 2010 (abstr 533)
11. Eidtmann H, de Boer R, Bundred N, et al: Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 21:2188-2194, 2010
12. Morgan G, Davies F, Gregory W, et al: Evaluating the effects of zoledronic acid (ZOL) on overall survival in patients (Pts) with multiple myeloma (MM): results of the Medical Research Council (MRC) Myeloma IX study. J Clin Oncol 28:578s, 2010 (abstr 8021)
13. Winter MC, Holen I, Coleman RE: Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34:453-475, 2008
14. US Food and Drug Administration: Background document for meeting of Advisory Committee for Reproductive Health Drugs: Denosumab. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM176595.pdf
15. Gonzalez-Suarez E, Jacob AP, Jones J, et al: RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468:103-107, 2010
16. Thomas D, Henshaw R, Skubitz K, et al: Denosumab in patients with giant-cell tumour of bone: An open-label, phase 2 study. Lancet Oncol 11:275-280, 2010
17. Raje N, Vallet S: Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther 12:586-597, 2010